Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dentium Co. Ltd. (145720.KS)
Dentium Co., Ltd., based in Seoul, South Korea, is a prominent global manufacturer and supplier of cutting-edge dental implant solutions. The company's extensive product range encompasses various dental implant systems, such as Superline, Implantium, Simpleline II, Slimline, Overdenture System, NR Line, and Implantium II. Dentium also develops a comprehensive assortment of surgical instruments, offering specialized kits for procedures like sinus lifts, osteotomy, and restoration, alongside individual tools such as harvest drills, surgical guides, and GBR systems. Additionally, they provide essential regenerative products like bone grafts, membranes, and tissue regeneration materials. Their portfolio is further enhanced by digital dentistry tools, laboratory supplies, iCT motors, and injections. Founded in 2000, the company initially operated as Biostech Co., Ltd. before adopting its current name, Dentium Co., Ltd., in August 2002.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.04% | +3.94% | -0.94% | +6.88% | -4.17% | +10.00% | -17.11% | -64.89% | -8.49% | +53.04% | +53.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | -2 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-15.1% Q1'26: -7.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-76.9% Q1'26: +36.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-6.6% Q1'26: -28.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.0% ★ Q1'26: +22.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.9% Q1'26: +6.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: -0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.30× Q1'26: 4.54× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
150.65B
est: 151.29B (-0.4%)
|
186.32B
est: 187.81B (-0.8%)
|
252.59B
est: 255.30B (-1.1%)
|
229.75B
est: 230.80B (-0.5%)
|
291.53B
est: 276.95B (+5.3%)
|
355.87B
est: 358.93B (-0.9%)
|
393.19B
est: 383.19B (+2.6%)
|
407.81B
est: 407.84B (0.0%)
|
346.45B
est: 337.23B (+2.7%)
|
381.10B
369.77B – 392.90B
+13.0% YoY
|
441.80B
401.66B – 473.00B
+15.9% YoY
|
609.00B
571.08B – 640.72B
+37.8% YoY
|
561.00B
526.07B – 590.22B
-7.9% YoY
|
| EBITDA |
45.65B
est: 49.92B (-8.6%)
|
48.61B
est: 61.97B (-21.6%)
|
50.88B
est: 84.24B (-39.6%)
|
47.73B
est: 76.15B (-37.3%)
|
93.61B
est: 91.38B (+2.4%)
|
140.97B
est: 118.43B (+19.0%)
|
162.80B
est: 126.43B (+28.8%)
|
126.72B
est: 138.20B (-8.3%)
|
87.39B
est: 114.27B (-23.5%)
|
129.14B
125.30B – 133.14B
+13.0% YoY
|
149.70B
136.10B – 160.28B
+15.9% YoY
|
206.36B
193.51B – 217.11B
+37.8% YoY
|
190.10B
178.26B – 200.00B
-7.9% YoY
|
| EBIT |
36.31B
est: 42.12B (-13.8%)
|
43.39B
est: 52.29B (-17.0%)
|
38.76B
est: 71.08B (-45.5%)
|
34.09B
est: 64.26B (-47.0%)
|
80.79B
est: 77.11B (+4.8%)
|
125.19B
est: 99.93B (+25.3%)
|
141.91B
est: 106.68B (+33.0%)
|
103.52B
est: 116.09B (-10.8%)
|
62.20B
est: 95.99B (-35.2%)
|
108.48B
105.26B – 111.84B
+13.0% YoY
|
125.76B
114.33B – 134.64B
+15.9% YoY
|
173.35B
162.56B – 182.38B
+37.8% YoY
|
159.69B
149.74B – 168.00B
-7.9% YoY
|
| Net Income |
30.07B
est: 23.29B (+29.1%)
|
34.25B
est: 26.94B (+27.2%)
|
14.79B
est: 21.58B (-31.5%)
|
22.54B
est: 18.49B (+21.9%)
|
55.48B
est: 38.31B (+44.8%)
|
86.07B
est: 82.58B (+4.2%)
|
96.52B
est: 77.45B (+24.6%)
|
72.71B
est: 62.73B (+15.9%)
|
16.80B
est: 34.39B (-51.1%)
|
63.50B
56.89B – 71.67B
+84.6% YoY
|
77.69B
60.17B – 86.12B
+22.4% YoY
|
165.05B
151.70B – 176.23B
+112.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
27.37B
est: 26.83B (+2.0%)
|
38.80B
est: 33.31B (+16.5%)
|
53.08B
est: 45.27B (+17.2%)
|
40.30B
est: 40.93B (-1.5%)
|
58.24B
est: 49.11B (+18.6%)
|
56.95B
est: 63.65B (-10.5%)
|
64.57B
est: 67.95B (-5.0%)
|
76.35B
est: 90.23B (-15.4%)
|
136.83B
est: 74.61B (+83.4%)
|
84.31B
81.81B – 86.93B
+13.0% YoY
|
97.74B
88.86B – 104.65B
+15.9% YoY
|
134.73B
126.35B – 141.75B
+37.8% YoY
|
124.11B
116.39B – 130.58B
-7.9% YoY
|
| EPS |
3,686.00
est: 2,700.33 (+36.5%)
|
3,972.00
est: 3,123.41 (+27.2%)
|
1,714.50
est: 2,502.00 (-31.5%)
|
2,614.22
est: 2,144.00 (+21.9%)
|
6,433.76
est: 4,442.67 (+44.8%)
|
9,979.97
est: 9,575.17 (+4.2%)
|
11,192.00
est: 8,981.00 (+24.6%)
|
8,430.18
est: 7,274.00 (+15.9%)
|
1,948.32
est: 3,988.25 (-51.1%)
|
7,363.00
6,596.66 – 8,310.08
+84.6% YoY
|
9,009.00
6,976.90 – 9,986.32
+22.4% YoY
|
19,139.00
17,589.88 – 20,434.84
+112.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-14 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 145720.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
